AbCellera Biologics Inc. (ABCL) Stock Profile — Insider Trades & Financials

Revenue$44.9M

Net Income-$8.9M

EPS$-0.49

Market Cap$1.0B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Carl Hansen

CEO & Executive Director

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

Founded: 2012
Employees: 596
Headquarters: VANCOUVER, A1, British Columbia, Canada
Website

⚡

Core Efficiency

ROE?

-0.93%

ROA?

-0.66%

D/E Ratio?

0.40

Op. Margin?

-63.72%

📊

Profitability Ratios

Net Margin?

-19.94%

Loading company sections...

AbCellera Biologics Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness